1. Home
  2. EVGN vs MBRX Comparison

EVGN vs MBRX Comparison

Compare EVGN & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Evogene Ltd

EVGN

Evogene Ltd

HOLD

Current Price

$0.46

Market Cap

11.1M

Sector

Industrials

ML Signal

HOLD

Logo Moleculin Biotech Inc.

MBRX

Moleculin Biotech Inc.

HOLD

Current Price

$0.57

Market Cap

10.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVGN
MBRX
Founded
1999
2015
Country
Israel
United States
Employees
N/A
N/A
Industry
Agricultural Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.1M
10.1M
IPO Year
2013
2016

Fundamental Metrics

Financial Performance
Metric
EVGN
MBRX
Price
$0.46
$0.57
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$3.50
★ $61.00
AVG Volume (30 Days)
82.3K
★ 1.0M
Earning Date
05-20-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$73.33
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.37
$0.16
52 Week High
$1.50
$7.98

Technical Indicators

Market Signals
Indicator
EVGN
MBRX
Relative Strength Index (RSI) 35.70 40.54
Support Level $0.37 $0.16
Resistance Level $0.86 $0.67
Average True Range (ATR) 0.04 0.10
MACD -0.01 0.00
Stochastic Oscillator 2.01 22.28

Price Performance

Historical Comparison
EVGN
MBRX

About EVGN Evogene Ltd

Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the industrial segment, followed by Agriculture.

About MBRX Moleculin Biotech Inc.

Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.

Share on Social Networks: